SIGA Technologies Inc represents values focused on innovation, scientific excellence, and commitment to public health. The company's corporate philosophy revolves around developing solutions for critical unmet needs in infectious diseases. SIGA Technologies Inc is dedicated to pioneering advancements in antiviral therapies, particularly for the prevention and treatment of potentially life-threatening viral infections. With a strong emphasis on research and development, SIGA Technologies Inc aims to improve global health outcomes by providing effective therapeutics to combat viral outbreaks.

SIGA Technologies Inc is primarily present in the United States. As a leading pharmaceutical company, SIGA Technologies Inc focuses on the development and commercialization of innovative solutions for public health challenges. With its headquarters located in New York, the company has a strong presence across the United States, collaborating with government agencies and healthcare organizations. SIGA Technologies Inc's commitment to delivering effective therapeutics has positioned it as a trusted player in the industry, constantly striving to improve global health outcomes.

SIGA Technologies Inc has achieved several significant milestones over the years. Firstly, the company successfully developed and obtained FDA approval for TPOXX, a drug used to treat smallpox infection. This milestone marked a major breakthrough in the field of biodefense. Additionally, SIGA Technologies has formed strategic partnerships with various government agencies, including the Department of Defense and the National Institutes of Health, which further demonstrates the company's credibility and expertise in the healthcare sector. Furthermore, SIGA Technologies has achieved noteworthy financial milestones, with consistent revenue growth and the successful execution of multiple funding agreements. These achievements highlight SIGA Technologies Inc as a leading player in the biotech industry with a strong track record of success.

SIGA Technologies Inc is a renowned pharmaceutical company specializing in the development and commercialization of innovative antiviral therapeutics. Established in 1995, SIGA Technologies Inc has emerged as a leader in the field of biodefense, focusing on providing solutions for emerging viral threats. The company is dedicated to developing effective treatments for diseases such as smallpox, Ebola, and other lethal infections. SIGA Technologies Inc's extensive research and development efforts, coupled with collaborative partnerships, have resulted in breakthroughs in antiviral drugs. With a strong emphasis on public health preparedness, SIGA Technologies Inc continues to play a pivotal role in safeguarding communities from potential biothreats worldwide.

The main competitors of SIGA Technologies Inc in the market include companies such as Emergent BioSolutions Inc, Bavarian Nordic A/S, and MicroPort Scientific Corporation.

SIGA Technologies Inc is primarily active in the biotechnology and pharmaceutical industries.

SIGA Technologies Inc. is a pharmaceutical company specializing in the development and commercialization of antiviral medicines to combat serious diseases. Their business model revolves around creating novel therapeutics for use in biodefense, addressing public health emergencies, and catering to commercial markets. With a focus on antiviral platforms, SIGA Technologies actively works on researching, developing, and delivering treatments for infectious diseases with significant unmet medical needs. By leveraging their expertise in antiviral drug development and strategic partnerships, SIGA Technologies aims to provide innovative solutions to global health challenges.

P/E santykio šiuo metu SIGA Technologies apskaičiuoti negalima.

KUV šiuo metu negali būti apskaičiuotas SIGA Technologies.

AlleAktien kokybės įvertis SIGA Technologies yra 5/10.

Pajamos šiuo metu negali būti apskaičiuotos SIGA Technologies.

Pelnas šiuo metu negali būti apskaičiuotas SIGA Technologies.

SIGA Technologies Inc is a US biotech company specializing in the development of medications to combat infectious diseases. The company's business model is based on the development of antiviral and antibacterial medications that effectively treat infectious diseases and improve population health. The company is divided into three business areas: research and development, production, and distribution. In the research and development area, SIGA Technologies works with leading scientists worldwide to obtain the latest knowledge about viruses and bacteria and develop innovative treatment methods. This area is key to the company's success as it allows SIGA Technologies to focus on the detection and treatment of infectious diseases. SIGA Technologies' production area is responsible for the manufacturing of antiviral and antibacterial medications. The company has state-of-the-art production facilities and maintains close relationships with suppliers to ensure the rapid production of high-quality medications. Production is an important business area as it ensures that medications are available when needed. In the distribution area, SIGA Technologies collaborates with partners such as the US government, international organizations like the World Health Organization (WHO), and other governments to ensure the distribution of medications. Collaboration with the US government is particularly important for SIGA Technologies as the company benefits from the government's biodefense program progress and makes a significant contribution to national security. SIGA Technologies' key products include TPOXX and ST-246. TPOXX is a medication for treating smallpox viruses approved by the FDA in 2018. ST-246 is an antiviral agent that can be used to treat smallpox viruses, herpes viruses, and other viral infections. Furthermore, SIGA Technologies is also working on the development of new medications targeting the treatment of other infectious diseases such as Ebola and Zika. These projects are still in development but have the potential to bring significant advancements in the treatment of infectious diseases. Overall, SIGA Technologies has a robust business model with clear focuses on research, production, and distribution of antiviral and antibacterial medications. The company has proven its ability to develop innovative solutions for combating infectious diseases and provides reliable support to governments and international organizations in fighting epidemics and infectious diseases.

SIGA Technologies moka dividendą 0 USD, kuris yra paskirstytas per išmokas per metus.

Dividenda šiuo metu negali būti apskaičiuota SIGA Technologies arba įmonė dividendų nemoka.

SIGA Technologies ISIN yra US8269171067.

SIGA Technologies WKN yra 919473.

SIGA Technologies akcijų simbolis yra SIGA.

Per paskutinius 12 mėnesių SIGA Technologies išmokėjo dividendą, kurios dydis siekė . Tai atitinka maždaug dividendų grąžą. Artimiausiems 12 mėnesiams SIGA Technologies tikėtina išmokės dividendus, kurie sudarys 0,45 USD.

SIGA Technologies šiuo metu yra dydžio dividendų grąža.

SIGA Technologies moka dividendus kas ketvirtį. Jie išmokami mėnesiais.

SIGA Technologies per paskutiniuosius 5 metus kiekvienais metais mokėjo dividendus.

Artimiausiems 12 mėnesiams tikimasi dividendų, kurių dydis yra 0,45 USD. Tai atitinka 6,99 % dividendų grąžos procentą.

SIGA Technologies priskiriamas sektoriui "Sveikata".

Norėdamas gauti paskutinį SIGA Technologies dividendą nuo 2024-04-11, kurio dydis yra 0,6 USD, turėjai turėti akciją savo depozite prieš ex-dieną, kuri buvo 2024-03-25.

Paskutinės dividendų išmokėjimas įvyko 2024-04-11.

2023 metais SIGA Technologies išmokėjo 0,45 USD dividendų.

SIGA Technologies dividendai yra mokami USD.